preclinical data

ArriVent BioPharma wins FDA clearance for ARR-002, a first-in-class dual-target ADC targeting ovarian and endometrial cancers, with Phase 1 trials expected in H2 2026.

Kymera Therapeutics showcases KT-579 preclinical data matching approved IBD therapies ahead of Phase 1 trials in late 2026.

Nurix Therapeutics unveils preclinical data showing protein degradation pipeline effectiveness, with NRX-0305 achieving 142% lifespan extension in melanoma models.

Prelude Therapeutics shows complete tumor regressions with PRT13722, a first-in-class oral KAT6A degrader, planning IND filing mid-2026 and clinical trials by year-end.

Nanobiotix presented preclinical data showing its Nanoprimer platform reduces liver toxicity and improves bioavailability of LNP-delivered DNA immunotherapies in mouse models.

Nanobiotix reports preclinical data showing nanoprimer technology improves DNA immunotherapy circulation while reducing hepatic toxicity in mouse models.

Sutro Biopharma presented encouraging preclinical data for its ADC pipeline at AACR 2026, with lead candidate STRO-004 showing robust antitumor activity and plans for IND submissions in 2026.

Acrivon highlights preclinical data for ACR-368 and ACR-2316 combination therapies at AACR 2026, showing synergies with checkpoint inhibitors and ADCs.

Zymeworks presents six ADC program updates at AACR 2026, including Phase 1 ZW191 clinical data and novel RAS-targeting platform preclinical results.

Biolojic Design presents preclinical data for BD200, a dual-target cancer drug showing superior efficacy against resistant tumors. Clinical trials expected in H2 2026.

Cogent Biosciences highlights preclinical data for KRAS and HER2 inhibitors at AACR 2026, with IND submission planned for CGT1263.

Foghorn Therapeutics will present preclinical data on SMARCA2 and epigenetic degrader programs at AACR 2026, advancing pipeline with Eli Lilly partnership.

HUTCHMED to present preclinical data on first-in-class PI3K/PIKK therapy and updated Phase Ib/II surufatinib combination trial results at AACR Annual Meeting 2026.

SynCardia unveils next-generation Emperor artificial heart at major cardiology conference, advancing fully implantable technology for long-term heart failure treatment.

Cardiff Oncology's onvansertib shows preclinical promise in reversing HER2-low breast cancer resistance when combined with trastuzumab deruxtecan; data presentation scheduled for April 2026.

Acrivon Therapeutics presents preclinical data at AACR 2026 demonstrating strong synergy between its CHK1/2 and WEE1 inhibitors with ADC payloads and immunotherapies.